Americans largely trust their doctors but are skeptical of payers, drugmakers and hospital leadership — a divide fueled by ...

Function Health raised a $298 million Series B round, pushing its valuation into unicorn territory at $2.5 billion. The ...

Light chain amyloidosis is not cancer, but cancer drugs are this rare disease’s standard of care. The patient need for new treatment options has sparked R&D efforts at biotech and big pharmaceutical ...

The accelerated FDA approval of Bayer's Hyrnuo covers treatment of advanced cases of non-small cell lung cancer with HER2 ...

About 22 million Americans would face sharply higher healthcare costs if enhanced ACA tax credits expire at the end of the ...

Efforts to innovate in the fight against influenza include universal influenza vaccines — none successful so far. Merck is aiming for universality with a drug, not a vaccine, via the $9.2 billion ...

Thirteen House Democrats introduced eight bills to rein in Medicare Advantage and bolster traditional Medicare.

Iambic has encouraging early clinical data for its lead program, a breast cancer drug that could offer advantages over other therapies in its class. Now the biotech has $100 million to support further ...

The CDC has caused outrage from many in the medical community after changing its webpage on Wednesday to include language that links vaccines to autism, despite numerous studies showing that there’s ...

In an interview, Munich Re Specialty Senior Vice President Jim Craig talked about the risk that accompanies innovation and the important role that insurers play.